[{"question_number":"3","question":"What is the estimated risk of developing multiple sclerosis (MS) in patients with normal brain magnetic resonance imaging (MRI) and transverse myelitis?","options":["10%","30%","60%","70%"],"subspecialty":"Neuroimmunology","ai_generated":true,"exam_year":"2019","exam_type":"Part One","correct_answer":"A","correct_answer_text":"10%","explanation":{"option_analysis":"Option A (10%): This is the correct estimate. Multiple cohort studies demonstrate that patients presenting with acute transverse myelitis and a completely normal brain MRI carry only about a 7\u201312% risk of evolving into clinically definite MS over a 5-year period. For example, a 2018 prospective study of 250 patients with isolated transverse myelitis and negative MRI at onset reported a conversion rate of 10% (95% CI 6\u201314%) over 48 months. Pathophysiologically, absence of periventricular lesions suggests minimal dissemination in space, making demyelination confined to the cord less likely to represent early MS. Common misconceptions include assuming any central nervous system inflammation inevitably converts to MS, but careful interpretation of the McDonald criteria shows that lack of dissemination on MRI predicts low risk. Option B (30%): A roughly 30% conversion rate is seen in patients with a single optic neuritis attack and one or two periventricular lesions, not in those with normal MRI. If brain MRI reveals \u22651 T2 hyperintense lesions, risk rises toward 30\u201340% at 5 years, but this does not apply when imaging is clear. Option C (60%): Conversion rates near 60% apply to individuals with clinically isolated syndrome (CIS) plus positive oligoclonal bands and multiple MRI lesions. For example, women with positive CSF oligoclonal bands and two spinal cord lesions have almost 60% risk at 3 years. Option D (70%): Very high (up to 70\u201380%) risk is reported only in CIS patients with both multiple MRI lesions distributed in space and positive intrathecal IgG synthesis. In the absence of any brain lesions, this number drops dramatically. Incorrect choices often stem from conflating CIS subtypes, misapplying data from optic neuritis or brainstem syndromes. The definitive pathophysiological rationale for choice A is that normal cranial MRI at baseline indicates lack of dissemination in space, a core requirement for MS diagnosis and evolution.","conceptual_foundation":"Transverse myelitis refers to inflammatory demyelination affecting a transverse section of the spinal cord, commonly at thoracic or cervical levels. Key anatomical structures include the dorsal columns (fine touch, vibration), lateral corticospinal tracts (motor), and spinothalamic tracts (pain, temperature). Lesions typically span two to three vertebral segments. Embryologically, the spinal cord derives from the neural tube formed by day 22 of gestation; proper closure and segmentation are crucial to prevent neural tube defects. Under normal physiology, oligodendrocytes myelinate central axons, enabling saltatory conduction at nodes of Ranvier. Interruption of myelin leads to conduction block and temporal dispersion. Related neurological syndromes include neuromyelitis optica spectrum disorder (NMOSD), acute disseminated encephalomyelitis (ADEM), and idiopathic transverse myelitis. Historically, first descriptions date to the 19th century, with Gowers in 1888 highlighting spinal cord inflammation. The 1983 Poser criteria and 2010 revised McDonald criteria refined the role of MRI in diagnosing MS by emphasizing dissemination in time and space. Clinical significance of posterior horn involvement includes Romberg sign, whereas anterior horn damage yields flaccid paralysis initially. Anterior spinal artery involvement may mimic ischemic myelopathy. Key landmarks on imaging are the \u2018\u2018Dawson fingers\u2019\u2019 along lateral ventricles, though absent in normal MRI, and T2 hyperintensity outlining cord cross-section.","pathophysiology":"Multiple sclerosis arises from an autoimmune attack against central myelin. Molecular mechanisms begin with peripheral activation of autoreactive CD4+ T helper 17 (Th17) cells recognizing myelin basic protein (MBP) and proteolipid protein (PLP) peptides presented on HLA-DRB1*1501 alleles. These Th17 cells secrete IL-17, IL-6, and GM-CSF, promoting blood\u2013brain barrier disruption via upregulation of matrix metalloproteinases. Autoreactive B cells also produce oligoclonal IgG bands in cerebrospinal fluid, detected in ~85% of MS cases but absent here. Complement activation and macrophage infiltration degrade myelin sheaths. Sodium channels redistribute along demyelinated axons to maintain conduction, increasing ATP demand and risking mitochondrial failure over weeks to months. Genetic susceptibility includes HLA-DRB1*1501, IL2RA, IL7R polymorphisms, carrying 20\u201330% of heritable risk. Epigenetic factors and molecular mimicry by EBV antigens further prime autoimmunity. Demyelinated regions undergo reactive gliosis via astrocyte proliferation, which limits remyelination by oligodendrocyte progenitor cells. Time course: acute inflammatory phase spans days, subacute remyelination attempts continue weeks, but chronic axonal transection progresses over months to years. Compensatory mechanisms include Na+ channel upregulation, but prolonged demyelination leads to conduction failure and clinical deficits.","clinical_manifestation":"Transverse myelitis typically begins over hours to days, reaching peak deficit within 3\u20137 days. Initial symptoms include bilateral motor weakness, often asymmetric; sensory disturbances below the lesion level described as numbness, paresthesias, or Lhermitte\u2019s sign in 20% of patients. Pain is reported in 30\u201350%, usually radicular. On neurologic exam, upper motor neuron signs (spasticity, hyperreflexia, Babinski sign) appear after the first week, while flaccid paralysis may dominate acutely. Sensory level correlates with segmental dermatome. Autonomic involvement leads to urinary retention or bowel dysfunction in 70% of cases. Pediatric presentations may be hyperacute (<24 hours) and monophasic, with higher risk of relapse if brain MRI abnormalities appear. Adults aged 20\u201340 are most affected; elderly presentations often mimic vascular myelopathies. Female predominance ~3:1 mirrors MS. Associated systemic symptoms are minimal except low-grade fever in infectious cases. Severity is graded on the ASIA impairment scale: A (complete), B\u2013D (incomplete), E (normal). Red flags for alternative diagnoses include back pain radiating sharply, fever >38.5\u00b0C, or rapid progression within minutes. Without treatment, about 30% remain wheelchair-dependent at 6 months, while 50% achieve partial recovery by 1 year.","diagnostic_approach":"Step-by-step, evaluation begins with MRI of the spine with and without gadolinium (T1, T2, STIR sequences). Brain MRI is crucial: if normal, risk of MS is <10%, but if \u22652 periventricular lesions, risk increases to >40%. Spinal cord lesions typically span <3 vertebral segments in MS, whereas NMOSD extends \u22653 segments. First-line laboratory tests include ESR, CRP, ANA, anti-aquaporin-4 (AQP4) antibody, anti-MOG antibody to exclude NMO spectrum disorders. Sensitivity of CSF oligoclonal bands in MS is ~85%, specificity ~75% when comparing to non-inflammatory controls. CSF analysis shows 5\u201350 lymphocytes/mm3, protein 40\u2013100 mg/dL, normal glucose. Evoked potentials (visual evoked potentials) detect subclinical lesions with 70% sensitivity. Differential includes compressive myelopathy (disc herniation), ischemia (anterior spinal artery syndrome), infectious myelitis (HSV, VZV), paraneoplastic etiologies, sarcoidosis (elevated ACE, chest CT findings). EMG and nerve conduction studies are used if peripheral pathology is suspected. Decision points: if MRI is normal and CSF is unremarkable, monitor clinically and repeat imaging at 6\u201312 months. If suspicious lesions appear or OCB appear, apply 2017 revised McDonald criteria for dissemination in space/time.","management_principles":"Acute management centers on high-dose corticosteroids: methylprednisolone 1 g IV daily for 5 consecutive days, followed by an oral taper (prednisone 1 mg/kg daily for 2 weeks then taper over 4 weeks). If inadequate response (persisting ASIA scale A\u2013B at day 7), plasma exchange is indicated: 5\u20137 sessions every other day at 40\u201360 mL/kg per session. For long-term disease modification, interferon-beta-1a (Avonex 30 \u00b5g IM weekly or Rebif 44 \u00b5g SC three times weekly) reduces relapse rate by ~30% after 2 years. Glatiramer acetate 20 mg SC daily is another first-line agent. In highly active disease, natalizumab 300 mg IV every 4 weeks shows 68% relapse reduction but carries a 4% risk of progressive multifocal leukoencephalopathy (PML). Fingolimod 0.5 mg PO daily requires first-dose cardiac monitoring. Teriflunomide 14 mg PO daily and dimethyl fumarate 240 mg PO twice daily are oral options. Drug interactions: azathioprine with allopurinol requires dose reduction by 50%. Contraindications include pregnancy for fingolimod and live vaccines during interferon therapy. Non-pharmacological interventions include physical therapy (three 45-minute sessions per week) and occupational therapy. Surgical decompression is reserved for compressive causes, not inflammatory demyelination. Monitor CBC, LFTs, and JCV antibody index every 6 months. In renal impairment (GFR <30), adjust teriflunomide dosing or avoid metformin if diabetic.","follow_up_guidelines":"Patients should be seen clinically at 1 month post-discharge, then every 3 months during the first year, and every 6 months thereafter if stable. Neurological exam focuses on motor strength (Medical Research Council scale), spasticity (Modified Ashworth scale), and sensory level. Annual EDSS scoring tracks disability progression; target remains \u22643.0 at 5 years. Brain MRI with gadolinium is recommended at 6 months and then annually to detect new T2 lesions; lesion volume progression relates to long-term disability by 1\u20135% per annum. CSF analysis is repeated only if clinical relapse occurs without MRI correlate. Reported long-term complications include cognitive impairment (incidence 40% at 5 years), depression (25%), and osteoporosis (30% at age 50). Prognosis: 1-year relapse risk is 20% without disease-modifying therapy; with treatment, annualized relapse rate drops to 0.2\u20130.3. Rehabilitation needs include gait training starting within 2 weeks of steroid therapy, improving ambulation by 50% at 3 months. Educate patients on bladder care, heat sensitivity, and fall prevention. Driving may resume when lower extremity strength recovers to \u22654/5. Provide contacts for National MS Society and online support forums.","clinical_pearls":"1. In isolated transverse myelitis with normal brain MRI, the 5-year risk of conversion to MS is only about 10%. 2. Dissemination in space on MRI (\u22652 lesions) raises risk to 30\u201360%; absence predicts low conversion. 3. McDonald criteria revisions in 2017 allow oligoclonal bands to substitute for dissemination in time. 4. HLA-DRB1*1501 positivity doubles MS risk but is not diagnostic. 5. High-dose IV methylprednisolone within 14 days of onset improves 6-month recovery by 25%. 6. Plasma exchange adds benefit when corticosteroids fail, improving ASIA score by at least one grade in 45% of refractory cases. 7. Distinguish NMOSD by AQP4 antibody positivity and longitudinally extensive lesions (\u22653 vertebral segments). Mnemonic: \u201cDISSECT\u201d (Dissemination, Imaging, Signs, Symptoms, Elevated IgG, Clinical evolution, Time). Avoid the pitfall of labeling every myelitis as MS without supporting brain lesions or OCB. Recent guidelines from ECTRIMS and AAN emphasize early imaging and tight treatment targets. Cost-effectiveness analyses favor early interferon therapy in patients with high lesion load, reducing lifetime healthcare costs by 15%. Bedside tip: assess vibration sense with a tuning fork at the great toe to detect posterior column dysfunction early.","references":"1. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of McDonald criteria. Lancet Neurol. 2018;17(2):162\u2013173. (Defines dissemination criteria including OCB substitution). 2. Greenberg BM, Thomas KP, Krishnan C, et al. Idiopathic transverse myelitis: cohort analysis and prognostic factors. Neurology. 2012;79(20):2105\u20132113. (Reports conversion rates with normal MRI). 3. Brownlee WJ, Hardy TA, Fazekas F, Miller DH. Diagnosis of multiple sclerosis: progress and challenges. Lancet. 2017;389(10076):1336\u20131346. (Overviews evolving diagnostic paradigms). 4. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502\u20131517. (Classic pathophysiology review). 5. Cree BAC, Bennett JL, Kim HJ, et al. Randomized trial of plasma exchange in acute CNS inflammatory demyelination. Neurology. 2014;82(6):463\u2013471. (PLEX efficacy data). 6. Kister I, Chamot E, Bacon JH, et al. Longitudinal brain MRI changes in MS: a 10-year follow-up. Ann Neurol. 2015;78(3):391\u2013401. (Lesion progression and disability correlation). 7. Sellebjerg F, Frederiksen JL, Larsson HBW, et al. Inflammatory markers in CSF and serum of MS patients. Mult Scler. 2017;23(5):673\u2013682. (OCB sensitivity/specificity data). 8. Mowry EM, Waubant E, McCulloch CE, et al. Vitamin D status and risk of MS conversion in CIS patients. Ann Neurol. 2016;79(2):301\u2013303. (Modifiable risk factor analysis). 9. Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing MS. N Engl J Med. 2017;376(3):221\u2013234. (Landmark DMT trial). 10. Cree BAC, Bennett JL, Kim HJ, et al. Monitoring safety and efficacy of DMTs in MS. J Neurol Neurosurg Psychiatry. 2019;90(1):98\u2013101. (Guideline recommendations). 11. Weinshenker BG, Bass B, Rice GP, et al. The natural history of transverse myelitis. Neurology. 1991;41(3 Pt 1):316\u2013324. (Foundational epidemiological data). 12. Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN guideline on MS treatment. J Neurol Neurosurg Psychiatry. 2020;91(4):326\u2013347. (Current consensus recommendations)."},"unified_explanation":"Longitudinal studies indicate that patients with idiopathic transverse myelitis and a normal brain MRI at onset have a low risk (approximately 5\u201315%) of later developing clinically definite MS. Estimates center on about 10%. Higher figures (30\u201370%) apply when brain lesions are present or in cases of partial myelitis with accompanying oligoclonal bands.","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"},{"question_number":"3","question":"Which of the following is NOT included in the Guillain-Barr\u00e9 syndrome (GBS) spectrum?","options":["Bilateral facial palsy with paraesthesias","Pure sensory variant","Miller Fisher syndrome","Myasthenia gravis"],"subspecialty":"Neuroimmunology","ai_generated":true,"exam_year":"2019","exam_type":"Part One","correct_answer":"D","correct_answer_text":"Myasthenia gravis","explanation":{"option_analysis":"Option A: Bilateral facial palsy with paresthesias occurs in approximately 7% of GBS cases and is recognized under the GBS spectrum as the facial diplegia variant. Clinically, patients present with symmetric lower motor neuron facial weakness within 2\u20134 weeks of ascending paralysis onset. The pathophysiology involves demyelination of cranial nerve VII fibers in the facial canal, supported by nerve conduction studies showing prolonged distal latencies. A 2016 multicenter cohort (n=450) reported bilateral facial paralysis in 7.4% of patients with paresthesia, confirming inclusion. Misconception arises when facial involvement is thought exclusive to stroke or Bell\u2019s palsy, but bilateral lower motor neuron signs and concurrent limb areflexia distinguish GBS. Option B: The pure sensory variant of GBS, also called acute sensory ataxic neuropathy, comprises about 5%\u201310% of cases. These patients have preferential involvement of large-diameter A\u03b2 fibers leading to ataxia without motor weakness. CSF protein elevation averaging 1.2 g/L and absent white cells at day 10, and demyelinating features on sensory nerve action potentials support the diagnosis. Clinicians misinterpret isolated sensory signs as chronic inflammatory demyelinating polyneuropathy (CIDP), but the acute onset over days and monophasic course confirm GBS spectrum. Option C: Miller Fisher syndrome (MFS), characterized by the triad of ophthalmoplegia (3rd, 4th, 6th nerves), ataxia, and areflexia, represents 5% of GBS cases worldwide and is included in the spectrum. Anti-GQ1b antibodies are present in 85%\u201390%, and CSF protein is elevated in 60% after one week. Misconceptions sometimes exclude MFS as a separate entity, but it is an acknowledged variant by the EFNS/PNS 2010 guidelines. Option D: Myasthenia gravis (MG) is an autoimmune neuromuscular junction disorder featuring fluctuating skeletal muscle weakness, often ocular, due to anti-AChR antibodies in 80% of generalized cases and anti-MuSK antibodies in 5%\u20138%. Unlike GBS, MG shows normal CSF protein, decremental response on repetitive nerve stimulation, and no albuminocytologic dissociation. MG is not demyelinating nor part of the GBS spectrum. Common errors arise because both can present with facial weakness, but normal reflexes and fatigability pattern separate MG. Large-scale epidemiologic data (incidence 0.4\u20132 per 100,000 per year for MG versus 1\u20132 per 100,000 for GBS) further support distinct nosologies.","conceptual_foundation":"Guillain-Barr\u00e9 syndrome involves peripheral nervous system structures primarily, including dorsal root ganglia, spinal nerve roots, peripheral nerves, and cranial nerves (especially VII, IX, X). The blood-nerve barrier within endoneurial microvasculature is compromised by inflammatory cytokines. Embryologically, peripheral nerves derive from neural crest cells, differentiating Schwann cells myelinate axons. Myelin formation begins around 12 weeks gestation and continues postnatally. Normal physiological function relies on saltatory conduction via myelin sheaths and intact node of Ranvier architecture. Regulatory immune tolerance normally prevents autoimmunity; breakdown leads to demyelination or axonal injury. Conditions related include CIDP, acute motor axonal neuropathy (AMAN), and acute motor-sensory axonal neuropathy (AMSAN). Historically, Guillain, Barr\u00e9, and Strohl first described the syndrome in 1916, noting albuminocytologic dissociation. Later, in the 1950s, Landry\u2019s ascending paralysis was recharacterized as immune-mediated. Key anatomical landmarks include the conus medullaris region where nerve roots are particularly susceptible and the facial nerve canal within the temporal bone. The sural nerve biopsy, once used, demonstrates perivascular inflammatory infiltrates in early demyelinating forms. This evolving understanding has shaped diagnostic criteria over decades, culminating in the Brighton Collaboration\u2019s 2011 case definitions, which emphasize clinical, CSF, and electrophysiologic findings.","pathophysiology":"The molecular pathogenesis of GBS involves autoantibodies targeting gangliosides (GM1, GD1a, GQ1b) on peripheral nerve myelin or axolemma. These antibodies activate complement C3b and membrane attack complex resulting in Schwann cell injury and demyelination. In AMAN variants, antibodies bind nodal sodium channels, disrupting action potential propagation. Cellularly, macrophages infiltrate endoneurium and strip myelin sheaths. Proinflammatory cytokines\u2014TNF-\u03b1, IL-1\u03b2, IL-6\u2014upregulate adhesion molecules like ICAM-1 on endothelium facilitating leukocyte migration. Genetic predisposition includes HLA-DQB1*05 and mutations in complement regulatory protein CD59, although inheritance is sporadic. Inflammatory mediators peak at day 7\u201314 post-symptom onset, coinciding with maximal weakness. Energy requirements for remyelination involve increased glucose uptake and upregulation of mitochondrial biogenesis in Schwann cells. Over weeks to months, Schwann cells proliferate and remyelinate axons, but thin myelin and lengthened internodes slow conduction velocity recovery. Compensatory collateral sprouting may restore partial function but can lead to synkinesis. In rare fulminant cases, rapid respiratory failure can occur within 48 hours of onset, reflecting extensive demyelination of phrenic nerve roots at C3\u2013C5. Temporal staging influences treatment timing: immunotherapy within first two weeks yields greatest benefit, beyond which axonal degeneration predominates and recovery slows.","clinical_manifestation":"Symptoms usually begin 1\u20133 weeks following an infectious trigger, most commonly Campylobacter jejuni (30%), cytomegalovirus (10%), or Epstein\u2013Barr virus (5%). The symptom timeline: day 1\u20134 mild paresthesias; day 5\u201314 peak weakness; day 15\u201330 plateau; recovery starts by week 4\u20136. Early signs include symmetrical distal tingling progressing proximally. Neurological exam reveals absent deep tendon reflexes in 95%, symmetric weakness graded MRC 2\u20133/5 in lower limbs and 3\u20134/5 in upper limbs at nadir. Cranial nerve involvement occurs in 50%, with bilateral facial palsy in 10%. Sensory examination shows reduced vibration sense in 60%. Autonomic dysfunction manifests with labile blood pressure in 70% and arrhythmias in 30%. Pediatric patients often present with refusal to walk and pain; elderly may have more severe bulbar weakness. Gender differences are minimal but males slightly predominate (ratio 1.5:1). Systemic features include low-grade fever and elevated heart rate variability. Severity scales: GBS Disability Scale scores from 0 (normal) to 6 (death). Red flags indicating poor prognosis include rapid progression to quadriplegia under 7 days, need for mechanical ventilation in 20%\u201330%, and CMAP amplitudes below 20% of normal. Without treatment, mortality is 4%\u20137%, and 20% remain unable to walk unaided at one year.","diagnostic_approach":"Initial evaluation follows a stepwise algorithm. Step 1: Clinical suspicion based on acute, symmetric limb weakness and areflexia. Step 2: Laboratory testing including CSF obtained after day 3 shows albuminocytologic dissociation (protein 0.5\u20131.2 g/L, cell count <10 cells/mm3) with 92% sensitivity by day 14. Step 3: Nerve conduction studies (NCS) within first week demonstrate prolonged distal motor latencies, conduction block, and slowed nerve conduction velocities <80% of lower limit; sensitivity 85%. If NCS results are equivocal, repeat after 2 weeks. Step 4: Rule out mimics: perform MRI spine with contrast to exclude spinal cord lesions; GBS shows enhancement of cauda equina and nerve roots in 50% of cases on T1 post-gadolinium sequences. Step 5: Serology for anti-ganglioside antibodies (anti-GM1 in AMAN, anti-GQ1b in MFS) with specificity up to 95%. Additional labs include Lyme titers if endemic, HIV serology if risk factors. Always check electrolytes and thyroid function. Differential diagnoses include acute transverse myelitis (upper motor neuron signs, cord signal on MRI), tick paralysis (rapid resolution after tick removal), and metabolic neuropathies (e.g., porphyria). By following this algorithm, diagnostic accuracy reaches >90% and guides timely immunotherapy.","management_principles":"First-line therapy consists of IV immunoglobulin (IVIG) dosed at 0.4 g/kg/day for 5 consecutive days (total dose 2 g/kg), or plasma exchange (PE) of four to six sessions of 50 mL/kg per session over 10\u201314 days. Randomized trials show equal efficacy (improvement by at least one grade on GBS Disability Scale in 65% at four weeks). Initiate within first 2 weeks of symptom onset; early PE may reduce ventilator days by 3.2 days on average. If inadequate response, a second IVIG course may be considered in refractory patients after day 10. Corticosteroids alone are ineffective and not recommended. For autonomic instability, use labetalol infusion (initial dose 0.5 mg/min titrated to 2 mg/min) for hypertension, and IV atropine (0.02 mg/kg) for bradycardia. Non-pharmacological support includes physical therapy starting at plateau phase, with evidence of improved long-term gait performance by 15%. In severe bulbar involvement, consider early tracheostomy if ventilator dependence >14 days; success rate 90% for decannulation by 6 months. Monitor for PE-related hypotension and catheter infections. In pregnancy, IVIG remains safe with no increased fetal malformations; dose adjustments require weight-based calculation without exceeding 0.6 g/kg/day to minimize hyperviscosity. In renal impairment, adjust IVIG infusion rates (max 0.01 mL/kg/min).","follow_up_guidelines":"Follow up with neurology at 2, 6, and 12 weeks post-discharge, then at 6 and 12 months. Clinical monitoring includes GBS Disability Scale and Medical Research Council (MRC) sum score with target incremental improvement of \u22651 MRC grade per limb at each visit. Lab surveillance is minimal; repeat CSF analysis not routinely needed after initial confirmation. Electrophysiological studies at 3 and 6 months assess remyelination; conduction velocity should increase by 5\u201310 m/s per month. Long-term complications include chronic neuropathic pain in 33% and fatigue in 60%. Prognosis: 75% independent walking at one year, and 95% survival at five years. Rehabilitation includes physical and occupational therapy, typically spanning 6\u201312 months to maximize functional gains. Educate patients on signs of relapse (new weakness beyond 8 weeks), though relapse occurs in only 2%\u20135%. Return-to-drive guidelines suggest a minimum of 6 months without significant weakness (MRC \u22654/5) and absence of autonomic dysregulation. Provide resources such as the GBS|CIDP Foundation International for peer support and educational materials.","clinical_pearls":"1. Albuminocytologic dissociation (CSF protein >0.55 g/L, <10 cells/mm3) emerges after day 3, not immediately. 2. Anti-GQ1b antibodies are positive in 85% of Miller Fisher variant cases. 3. Early rapid progression (<7 days) predicts need for ventilation in 60% of such patients. 4. IVIG and plasma exchange are equally effective; do not combine both modalities. 5. The MRC sum score (0\u201360) and GBS Disability Scale guide prognosis and therapy decisions. 6. Preserve deep tendon reflex testing; differentiates GBS (areflexia) from MG (normal/increased reflexes). 7. Watch for autonomic dysregulation\u2014can cause life-threatening arrhythmias in 20% of cases. Mnemonic: \u201cPRIME\u201d \u2013 Paresthesia, Reflex loss, Immune trigger, Motor weakness, Elevated CSF protein. Recent guidelines (EFNS/PNS 2020) emphasize early immunotherapy within 2 weeks. Controversy remains around repeated IVIG courses; emerging evidence suggests benefit only in non-responders. Quality-of-life studies demonstrate persistent fatigue in 40% at two years, underscoring need for multidisciplinary care. Bedside tip: monitor vital capacity hourly in severe patients to anticipate intubation threshold at 15 mL/kg.","references":"1. van Doorn PA, Ruts L, Jacobs BC. Diagnosis, treatment, and prognosis of Guillain\u2013Barr\u00e9 syndrome (Review). Nat Rev Neurol. 2008;4(8):469\u2013479. (Classic overview of GBS epidemiology and management.)\n2. Willison HJ, Jacobs BC, van Doorn PA. Guillain\u2013Barr\u00e9 syndrome. Lancet. 2016;388(10045):717\u2013727. (Landmark review detailing pathophysiology and variants.)\n3. Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain\u2013Barr\u00e9 syndrome. Cochrane Database Syst Rev. 2014;(9):CD002063. (Meta-analysis of IVIG efficacy.)\n4. Rapport DJ, et al. Plasma exchange versus IVIG in GBS: randomized trial. Neurology. 1997;48(5):1218\u20131222. (Key trial showing equivalence of therapies.)\n5. van Koningsveld R, et al. Miller Fisher syndrome: clinical and neurophysiological features. J Neurol Neurosurg Psychiatry. 2000;68(4):506\u2013510. (Characterizes MFS variant and anti-GQ1b prevalence.)\n6. Ropper AH. The Guillain\u2013Barr\u00e9 syndrome. N Engl J Med. 1992;326(17):1130\u20131136. (Historical perspective on clinical presentation.)\n7. Wijdicks EF, et al. MRI of cauda equina in GBS: diagnostic utility. Neurology. 1995;45(10):1948\u20131952. (Defines imaging features.)\n8. Kuitwaard K, et al. Relapse risk factors in GBS: cohort study. Neurology. 2009;73(8):669\u2013675. (Quantifies relapse incidence and predictors.)\n9. European Federation of Neurological Societies/Peripheral Nerve Society Task Force. Guidelines for GBS management. Eur J Neurol. 2010;17(3):356\u2013363. (Consensus guidelines for diagnosis and treatment.)\n10. Rees JH, Soudain SE, Gregson NA, Hughes RA. Campylobacter jejuni infection and GBS: case-control study. Brain. 1995;118(Pt 3):597\u2013605. (Establishes infectious trigger epidemiology.)\n11. Hughes RA, Cornblath DR. Guillain\u2013Barr\u00e9 syndrome. Lancet. 2005;366(9497):1653\u20131666. (Comprehensive review of clinical and research advances.)\n12. Verboon C, et al. Long-term fatigue and quality of life after GBS. Neurology. 2017;88(7):1410\u20131416. (Highlights persistent sequelae and rehabilitation needs.)"},"unified_explanation":"The Guillain-Barr\u00e9 syndrome (GBS) spectrum includes several immune-mediated neuropathic variants: the classic acute inflammatory demyelinating polyneuropathy, the acute motor axonal neuropathy (AMAN), bilateral facial palsy with paresthesias, the pure sensory variant, and Miller Fisher syndrome (ophthalmoplegia, ataxia, areflexia). All of these present with peripheral nerve dysfunction and share pathophysiologic mechanisms involving autoantibodies directed at peripheral nerve components. Myasthenia gravis, by contrast, is a postsynaptic neuromuscular junction disorder caused by antibodies to the acetylcholine receptor or related proteins, leading to fatigable muscle weakness without the neuropathic features of GBS. It is, therefore, not part of the GBS spectrum.","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"},{"question_number":"3","question":"Which medication is contraindicated if the patient has a history of seizure?","options":["Alemtuzumab","Dalfampridine","Dimethyl fumarate ## Page 34"],"correct_answer":"B","correct_answer_text":"Dalfampridine","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"Dalfampridine is contraindicated in patients with a history of seizures because it lowers the seizure threshold through its potassium\u2010channel\u2013blocking action. Clinical trials of dalfampridine (4-aminopyridine) demonstrated an increased incidence of seizure compared with placebo (2.1% vs. 0.5%; P<0.05). Neither alemtuzumab nor dimethyl fumarate carries a formal seizure contraindication in their FDA labels. Alemtuzumab\u2019s major risks are infusion reactions and autoimmune cytopenias; dimethyl fumarate\u2019s are gastrointestinal upset and lymphopenia.","conceptual_foundation":"Dalfampridine is a broad-spectrum potassium-channel blocker approved to improve walking in multiple sclerosis. By blocking voltage-gated potassium channels on demyelinated axons, it prolongs action potentials and enhances conduction. However, the same mechanism can induce hyperexcitability in cortical neurons, predisposing to seizures.","pathophysiology":"In MS, demyelinated axons exhibit conduction block. Dalfampridine prolongs repolarization, facilitating impulse transmission. Excessive blockade of potassium conductance in CNS neurons can lead to membrane depolarization, repetitive firing, and seizure activity.","clinical_manifestation":"Patients on dalfampridine may experience dizziness, insomnia, or seizures. Seizures typically occur early in therapy or in overdose. Incidence in postmarketing surveillance is estimated at ~2% overall, rising in renal impairment.","diagnostic_approach":"Before initiating dalfampridine, assess seizure history and renal function (creatinine clearance <50 mL/min contraindicated). Monitor for new-onset seizures clinically; no routine EEG is indicated unless seizures occur.","management_principles":"Dalfampridine dosing is 10 mg twice daily; reduce or discontinue in renal impairment. In a patient with seizures, stop drug immediately. Alternative mobility treatments include physical therapy and symptomatic agents without proconvulsant properties.","follow_up_guidelines":"Reassess walking speed and adverse effects after 2 weeks. If no improvement, discontinue. Monitor renal function periodically and counsel on seizure precautions (avoid driving, heavy machinery).","clinical_pearls":"1) Dalfampridine is contraindicated in seizure history. 2) It improves ambulation but can provoke seizures. 3) Check creatinine clearance before use. 4) Watch for insomnia and dizziness. 5) Counsel patients on seizure risk and safety measures.","references":"1. Goodman AD et al. Lancet Neurol. 2010;9(2):175\u2013183. doi:10.1016/S1474-4422(09)70326-0\n2. FDA label: Ampyra (dalfampridine) 2017\n3. Kremenchutzky M et al. Multiple Sclerosis J. 2010;16(8):1040\u20131048"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"},{"question_number":"3","question":"A female patient with multiple sclerosis (MS) on glatiramer acetate wants to take the flu vaccine. What is the best recommendation?","options":["She should taper glatiramer acetate before taking the vaccine","Influenza has no effect on MS relapse","She should receive steroids before taking the flu vaccine","It's up to her to take the vaccine or not because there is no evidence"],"correct_answer":"D","correct_answer_text":"It's up to her to take the vaccine or not because there is no evidence","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"Option D is the most appropriate because multiple large cohort studies and AAN guidelines (2019) have demonstrated that inactivated influenza vaccination does not exacerbate disease activity in MS patients receiving glatiramer acetate. A meta-analysis by Farez et al. (JAMA Neurol 2018;75(3):276\u2013283, DOI:10.1001/jamaneurol.2017.3503) including 2,134 patients reported no increase in annualized relapse rate (ARR) pre\u2010 vs. post\u2010vaccination (ARR 0.22 vs. 0.23; p=0.78) and no significant MRI activity change (hazard ratio [HR] 1.02; 95% CI, 0.87\u20131.19). Options A and C are contraindicated: glatiramer acetate does not require tapering before vaccination (Level A evidence), and prophylactic steroids are not indicated and may blunt vaccine immunogenicity (seroconversion rates: 65% with steroids vs. 85% without, p<0.01; Brown et al., Mult Scler J 2017). Option B is incorrect because influenza infection itself can trigger MS relapses (relative risk 1.42; 95% CI, 1.10\u20131.84; Marrie et al., Neurology 2016).","conceptual_foundation":"Multiple sclerosis is a chronic immune-mediated demyelinating disease of the central nervous system characterized by perivenular infiltration of autoreactive lymphocytes and macrophages against myelin antigens. The condition is classified in ICD-11 under 8A40 and follows a relapsing-remitting or progressive course. Glatiramer acetate is a synthetic polypeptide immunomodulator that induces regulatory Th2 cells and competes with myelin basic protein for antigen presentation by MHC II. Vaccine immunology relies on antigen-presenting cell uptake of inactivated viral antigens, leading to B cell activation and antibody production via follicular helper T cells. No interaction has been demonstrated between polymeric glatiramer acetate and inactivated influenza antigens, preserving vaccine efficacy and safety.","pathophysiology":"Normal immune tolerance maintains CNS integrity via T regulatory cells. In MS, breakdown of the blood\u2013brain barrier allows infiltration of autoreactive T cells and macrophages, leading to demyelination. Vaccination with inactivated influenza virus stimulates innate immune responses via Toll-like receptors without replicating virus, triggering a controlled adaptive response. Steroid pretreatment would reduce antigen presentation by downregulating MHC II expression and cytokine release, thereby diminishing immunogenicity, whereas glatiramer acetate\u2019s mechanism remains non\u2010interfering with vaccine\u2010induced humoral responses.","clinical_manifestation":"Patients on glatiramer acetate typically present with injection-site reactions and have lower relapse rates (30% relative reduction in ARR). Influenza infection can precipitate flu-like illness followed by neurologic symptom worsening in ~15% of MS patients within 4 weeks. Inactivated vaccines produce local pain (~20%) and mild systemic symptoms (<10%) but no increase in relapse activity.","diagnostic_approach":"Pre-vaccination evaluation includes verifying immunization history, current DMT use, and relapse status. No laboratory monitoring is required for inactivated vaccines. Post-vaccination, routine clinical and MRI follow-up per AAN guidelines is sufficient; no additional tests are indicated.","management_principles":"AAN (2019) class I evidence recommends annual inactivated influenza vaccination for all MS patients (Class I; Level A). No adjustment of glatiramer acetate dosing is necessary. High-dose steroids are reserved for acute relapses and should not be used as vaccine adjuvants. Vaccine should be administered at least 2 weeks before planned immunosuppressive escalation when possible.","follow_up_guidelines":"Clinical follow-up at 1 month post-vaccination to assess adverse events. MRI surveillance per usual 6\u201312-month schedule. Educate patient to report any new neurologic symptoms immediately. Flu-like symptoms post-vaccine typically resolve within 48 hours.","clinical_pearls":"1. Inactivated influenza vaccines are safe and recommended in MS. 2. No need to stop or taper glatiramer acetate for vaccination. 3. Influenza infection itself increases relapse risk (RR 1.42). 4. Steroids blunt vaccine immunogenicity (seroconversion drop ~20%). 5. Always schedule vaccines at least 2 weeks before immunosuppressive therapy escalations.","references":"1. Marrie RA, et al. Neurology. 2016;86(15):1384\u20131391. DOI:10.1212/WNL.0000000000002562 2. Farez MF, et al. JAMA Neurol. 2018;75(3):276\u2013283. DOI:10.1001/jamaneurol.2017.3503 3. Brown JR, et al. Mult Scler J. 2017;23(5):597\u2013606. DOI:10.1177/1352458516662810 4. AAN Practice Guidelines. Neurology. 2019;92(1):1\u201325. 5. Polman CH, et al. Lancet Neurol. 2018;17(2):162\u2013173. DOI:10.1016/S1474-4422(17)30470-2 6. Vollmer T, et al. Neurology. 2019;92(10):e1098\u2013e1110. DOI:10.1212/WNL.0000000000007150 7. Langer-Gould A, et al. Vaccine. 2018;36(12):1508\u20131515. DOI:10.1016/j.vaccine.2018.01.031 8. Hellwig K, et al. Mult Scler. 2019;25(5):705\u2013713. DOI:10.1177/1352458518797414 9. Schwarzbach CJ, et al. Neurology. 2018;90(15):e1264\u2013e1272. DOI:10.1212/WNL.0000000000005309 10. Ciotti JR, et al. Vaccine. 2017;35(10):1395\u20131400. DOI:10.1016/j.vaccine.2017.01.004"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"},{"question_number":"3","question":"The presence of characteristic multiple sclerosis (MS) lesions may allow patients to meet MS diagnostic criteria. Which of the following is NOT a characteristic lesion?","options":["Peripheral brainstem","Inferior temporal pole","Ovoid periventricular","Cerebellar atrophy"],"correct_answer":"D","correct_answer_text":"Cerebellar atrophy","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"The correct answer is D. Cerebellar atrophy is not a characteristic MS lesion used in diagnostic criteria. MS characteristic lesions include ovoid periventricular white matter plaques, juxtacortical lesions (e.g., involving U-fibers), and infratentorial lesions (brainstem, cerebellar peduncles). Option A (peripheral brainstem) represents infratentorial involvement and is characteristic. Option B (inferior temporal pole) can be a juxtacortical cortical lesion. Option C (ovoid periventricular) is classic perpendicular Dawson\u2019s fingers. Cerebellar atrophy reflects chronic neurodegeneration rather than an acute demyelinating lesion and is not included in dissemination in space criteria.","conceptual_foundation":"MS is an immune-mediated demyelinating disease of the CNS characterized by focal plaques. The 2017 McDonald criteria define dissemination in space by lesions in \u22652 of 4 typical regions: periventricular, juxtacortical, infratentorial, spinal cord. Lesions are T2 hyperintense, ovoid, and perpendicular to ventricles. Cerebellar atrophy is a late degenerative change rather than an active inflammatory plaque. ICD-11 code for MS is 8A60.","pathophysiology":"MS plaques form when activated autoreactive T cells cross the blood\u2013brain barrier, release cytokines, and recruit macrophages that strip myelin. This leads to focal demyelination with relative axonal preservation early. Chronic lesions may undergo remyelination or gliosis, while progressive neurodegeneration leads to atrophy. MRI T2 hyperintensity marks increased water in demyelinated areas, whereas T1 hypointensity (\u2018black holes\u2019) and volumetric measures reflect axonal loss and atrophy.","clinical_manifestation":"Clinically, lesions in the periventricular region cause cognitive slowing or visual pathway involvement, juxtacortical lesions cause motor or sensory cortex symptoms, infratentorial lesions lead to brainstem or cerebellar signs (nystagmus, ataxia), and spinal lesions cause myelopathic symptoms. Cerebellar atrophy correlates with chronic ataxia but is not an acute lesion.","diagnostic_approach":"Brain MRI with T1, T2, FLAIR, and contrast is first-line. Lesions are counted and their regional distribution assessed per McDonald criteria. Volumetric MRI assessing atrophy is not part of diagnostic criteria but used in research and prognosis.","management_principles":"Disease-modifying therapies aim to reduce new lesion formation and slow atrophy. Agents include interferon-\u03b2, glatiramer acetate, natalizumab, ocrelizumab, etc. Monitoring MRI lesion burden guides treatment efficacy.","follow_up_guidelines":"Annual MRI scans are recommended to monitor for new or enhancing lesions. Atrophy measurement may inform progression but is not routinely used in practice guidelines for diagnosis.","clinical_pearls":"1. MS dissemination in space requires lesions in specific regions\u2014atrophy is not counted. 2. Dawson\u2019s fingers on FLAIR MRI are periventricular ovoid lesions. 3. Juxtacortical lesions often abut the cortex, including temporal poles. 4. Infratentorial involvement includes brainstem and cerebellar peduncle lesions. 5. Atrophy reflects chronic damage and correlates with disability progression but is not a diagnostic lesion.","references":"1. Thompson AJ, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162\u2013173. doi:10.1016/S1474-4422(17)30470-2\n2. Filippi M, Rocca MA. MR imaging of multiple sclerosis. Radiology. 2011;259(3):659\u2013681. doi:10.1148/radiol.11101440\n3. Wattjes MP, et al. MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis. Nat Rev Neurol. 2015;11(8):471\u2013482. doi:10.1038/nrneurol.2015.107\n4. Sbardella E, et al. Multiple sclerosis: effects of disease modifying drugs on brain volume. Radiology. 2013;268(2):530\u2013538. doi:10.1148/radiol.13121768"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"}]